PhRMA Lawyer Argues Mandatory Rebate Sharing Wouldn’t Violate Non-Interference Clause

July 09, 2018
The brand drug lobby explained in a July 2 blog why it believes the Trump administration’s proposal to force plans to share rebates at the point of sale would not interfere with price negotiations between brands and plans. Pharmaceutical Research and Manufacturers of America General Counsel James Stansel said the proposal wouldn't violate the so-called non-interference clause for two reasons: 1. the negotiations wouldn’t involve the government; and 2. the proposal wouldn’t interfere with drug placement on formularies.. Brands’ legal...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.